Moxidectin
An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.
Молекулярная масса
639,8000 g/mol
LogP
4,30
TPSA
116,00 Ų
Правило пяти Липинского
Соответствует
Терапевтические области
Механизм действия
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
2D Структура
Cite this structure
Embed this structure
SMILES
CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C
InChI
InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1
Molecular Formula
C37H53NO8
HBD / HBA
2 / 9
Вращаемые Связи
3
Тяжёлые Атомы
46
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Yes, Moxidectin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2104415. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9832912. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="moxidectin"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/moxidectin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/moxidectin/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/moxidectin/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="moxidectin"></drugfyi-drug>